Total raised
$34 M
2 rounds on record
Latest round
$25 M
Sep 2018
First round on record
Jul 2017
Today
Acquired
Acquired by Quanterix Corporation
Acquired Matched to this startup by its exact name; the buyer's report is the source.
Funding rounds 2 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Akoya Biosciences, Inc. Month Raised Raise Size Investors Sold Filing Sep 2018 $25 M No. 2 $10 to $50 million 6
Akoya Biosciences, Inc.: Raise no. 2, Sep 2018 × Investors in this round 6 investors had bought by the notice of Oct 2, 2018: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $25 M of $26 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian McKelligon · Executive Officer, Director Rob Hart · Executive Officer Garry Nolan · Director Matthew Winkler · Director Robert Shepler · Director Thomas Raffin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brian McKelligon, Chief Executive Officer. Newest notice filed Oct 2, 2018. Read the notice at the SEC .
equity SEC Jul 2017 $9 M No. 1 $2 to $10 million 6
Akoya Biosciences, Inc.: Raise no. 1, Jul 2017 × Investors in this round 6 investors had bought by the notice of Jul 14, 2017: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian McKelligon · Executive Officer Rob Hart · Executive Officer Garry Nolan · Director Matthew Winkler · Director Robert Shepler · Director Thomas Raffin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Rob Hart, Chief Financial Officer. Newest notice filed Jul 14, 2017. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Akoya Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2018).
SEC Form D · Oct 2018
The industry group it chose in its notices: Other.
SEC Form D · Oct 2018
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
No investor of Akoya Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Akoya Biosciences, Inc. Name Role Named in Brian McKelligon Executive officer Oct 2018 Rob Hart Executive officer Oct 2018 Brian McKelligon Director Oct 2018 Garry Nolan Director Oct 2018 Matthew Winkler Director Oct 2018 Robert Shepler Director Oct 2018 Thomas Raffin Director Oct 2018
Acquired (Jan 1, 2025). Acquired by Quanterix Corporation.